Restricted accessResearch articleFirst published online 1987-09
Evaluation of the Vasodilator vs Inotropic Effect of Milrinone Using an Animal Model of Left Ventricular Failure: Reversal of Disopyramide Depression of the Myocardium with Milrinone
Milrinone (M) has been shown to improve left ventricular (LV) performance in animal and human studies. M has strong vasodilator action, and whether increased LV performance is due primarily to vasodilation or to a direct positive inotropic effect is unclear.
Ten mongrel dogs were studied. Disopyramide caused a significant and sus tained decrease in LV function and was a good model for myocardial depres sion. At equal reduction in systemic vascular resistance (SVR), M reversed this LV depression to a significantly greater degree than nitroprusside (NP) did.
At equal levels of vasodilation, M produced significantly greater improve ment in indices of LV function than NP did in our model of disopyramide- induced LV failure. This suggests that its effect on LV function is not due entirely to afterload reduction, or to reflex sympathetic stimulation, but has a substantial component of direct inotropic stimulation. This study also demon strated a reversal of disopyramide-induced LV dysfunction by M, which may be clinically useful since, as in many antiarrhythmics, myocardial depression may be a limiting factor in its use.
Get full access to this article
View all access options for this article.
References
1.
Alousi AA, Helstosky A., Montenaro M., Cicero F.: Intravenous and oral cardiotonic activity of Win 47203, A potent amrinone analog in dogs. Fed Proc40:663, 1981.
2.
Baim D., McDowell A., Chemiles J., Monrad E., Parker J., Edelson J., Braunwald E., Grossman W.: Evaluation of a new bipyridine inotropic agent, milrinone, in patients with severe congestive heart failure. N Engl J Med309:748-756, 1983.
3.
Kubo S., Cody R., Chatterjee K., Simonton C., Rutman H., Leonard D.: Acute dose range study of milrinone in congestive heart failure. Am J Cardiol55:726-730, 1985.
4.
Alousi AA, Canter J., Monenaro M., Fort D., Ferrari R.: Cardiotonic activity of milrinone, a new and potent cardiac bipyridine, on the normal and failing heart of experimental animals. J Cardiovasc Pharm5:792-803, 1983.
5.
Podrid P., Schoenberger A., Lown B.: Congestive heart failure caused by oral disopyramide. N Engl J Med302:614-617, 1980.
6.
Walsh R., Horowitz L.: Adverse hemodynamic effects of intravenous disopyramide compared with quinidine in conscious dogs. CIRC60:1053-1058, 1979 .
7.
Befeler B., Castellanos A., Wells D., Vaguiero M., Yeh B.: Electrophysiologic effects of the antiarrhythmic agent disopyramide phosphate . Am J Card35:282, 1975.
8.
Mathur PP: Cardiovascular effects of a new antiarrhythmic agent disopyramide phosphate . Am Heart J84:764, 1972.
9.
Monrad E., Baim D., Smith H., Lanoue A., Braunwald E., Grossman W.: Effects of milrinone on coronary hemodynamics and myocardial energetics with patients with congestive heart failure. CIRC71:972-979, 1985.
10.
Monrad E., McKay R., Baim D., Colucci W., Fifer M., Heller G., Royal H., Grossman W.: Improvement in indexes of diastolic performance of patients with congestive heart failure treated with milrinone. CIRC70:1030-1037, 1984.
11.
Jaski B., Fifer M., Wright R., Braunwald E., Colucci W.: Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. J Clin Invest75:643-649, 1985.
